AYTU BIOPHARMA, INC
AYTUUS売上高
$66M
百万USD
営業利益
$-8M
百万USD
純利益
$-14M
百万USD
ROE
-71.5%
最新FY
EPS
-
USD / 株
配当
-
USD / 株
業績推移
収益性
キャッシュフロー
財務状況
四半期業績
| 年度 | 期 | 売上高 | 純利益 | EPS |
|---|---|---|---|---|
| FY2021 | Q1 | - | $-4M | - |
| FY2021 | Q2 | - | $-10M | - |
| FY2021 | Q3 | - | $-25M | - |
| FY2021 | FY | $66M | $-58M | - |
| FY2022 | Q1 | $22M | $-28M | $-1.09 |
| FY2022 | Q2 | $23M | $-12M | $-0.44 |
| FY2022 | Q3 | $24M | $-53M | $-1.79 |
| FY2022 | FY | $97M | $-110M | $-3.75 |
| FY2023 | Q1 | $28M | $-1M | $-0.28 |
| FY2023 | Q2 | $26M | $-7M | $-2.15 |
| FY2023 | Q3 | $23M | $-7M | $-1.93 |
| FY2023 | FY | $107M | $-17M | $-5.11 |
| FY2024 | Q1 | $22M | $-8M | $-1.48 |
| FY2024 | Q2 | $23M | $-0M | - |
| FY2024 | Q3 | $18M | $-3M | - |
| FY2024 | FY | $81M | $-16M | - |
| FY2025 | Q1 | $17M | $1M | $-0.15 |
| FY2025 | Q2 | $16M | $1M | $-0.26 |
| FY2025 | Q3 | $18M | $4M | $0.21 |
| FY2025 | FY | $66M | $-14M | - |
| FY2026 | Q1 | $14M | $2M | $-0.08 |
| FY2026 | Q2 | $15M | $-11M | $-1.05 |
| FY2026 | Q3 | $12M | $-6M | $-0.53 |
財務データ
| 指標 | FY2016 | FY2017 | FY2018 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| 売上高 | - | - | - | - | $66M | $97M | $107M | $81M | $66M |
| 営業利益 | $-22M | $-20M | $-20M | $-21M | $-59M | $-112M | $-17M | $-5M | $-8M |
| 純利益 | $-28M | $-23M | $-10M | $-14M | $-58M | $-110M | $-17M | $-16M | $-14M |
| 総資産 | $24M | $15M | $21M | $153M | $266M | $138M | $136M | $118M | $124M |
| 純資産 | - | - | - | - | - | $46M | $39M | - | - |
| 自己資本 | $10M | $4M | $13M | $95M | $138M | $46M | $39M | $28M | $19M |
| 営業CF | - | - | $-16M | $-28M | $-26M | $-29M | $-5M | $-1M | $-2M |
| EPS | - | - | - | - | - | $-3.75 | $-5.11 | - | - |
| BPS | $1.99 | $0.99 | $7.45 | $0.76 | $4.99 | $0.74 | $7.12 | $4.51 | $1.91 |
| ROE | -279.4% | -562.7% | -75.9% | -14.3% | -42.4% | -239.0% | -43.3% | -57.2% | -71.5% |